RBR-9ypbtf
Completed
Phase 2
Study of safety and immunogenicity of the vaccine against human papillomavirus (HPV) in patients with Systemic Lupus Erythematosus (JSLE) and Juvenile Dermatomyositis (JMD)
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Being female; Be between 9\-20 years old; Have been diagnosed with one of the following immune system disorders before the age of 17 and before their first quadrivalent vaccine against human papillomavirus: juvenile systemic lupus erythematosus or juvenile dermatomyositis; Have not received the three doses of the quadrivalent human papillomavirus vaccine
Exclusion Criteria
- •The absence of parental consent for those under 18 or consent from the patient or control; refusal of any blood collection; hx of suspected or proven cervical carcinoma; being pregnant
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Phase I Study: safety and immunogenicity of vaccination with XAGE1B long peptides combined with poly-ICLC in patients with pulmonary adenocarcinomalung carcinomanon small cell lung cancer1003866610029107NL-OMON45223eids Universitair Medisch Centrum30
Active, not recruiting
Not Applicable
Efficacy of the vaccine against Hepatitis B in patients under immunosuppressive treatment with past hepatitis B but low antibody titers. Assessment of the usefulness of developing higher antibody titers in the prevention of reactivation of hepatitis B.EUCTR2015-000557-21-ESVall de Hebron Hospital
Completed
Not Applicable
Study for effects of Haemophilus Influenzae type b conjugate vaccine in childreChildren Haemophilus Meningitis.Meningitis due to Haemophilus influenzaeIRCT201008084536N1Masoondarou Co.50
Completed
Phase 1
Investigating of the Immunogenicity and Safety of Lactococcus Lactis Vaccine Related to Human Papillomavirus Type 16IRCT20190504043464N1Iran University of Medical Sciences200
Completed
Not Applicable
Evaluation of efficacy and risks of vaccination for liver transplant recipientsiver transplant recipientsJPRN-UMIN000030485Kyoto University200